BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35583829)

  • 1. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.
    Tober R; Schnetzke U; Fleischmann M; Yomade O; Schrenk K; Hammersen J; Glaser A; Thiede C; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1569-1583. PubMed ID: 35583829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
    Rodríguez-Veiga R; Montesinos P; Boluda B; Lorenzo I; Martínez-Cuadrón D; Salavert M; Pemán J; Calvillo P; Cano I; Acuña E; Villalba A; Piñana JL; Sanz J; Solves P; Senent L; Vicente A; Sempere A; Cervera J; Barragán E; Jarque I; Torres A; Sanz MA; Sanz GF
    Ann Hematol; 2019 Sep; 98(9):2081-2088. PubMed ID: 31240471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
    Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
    Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
    Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
    Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
    J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
    Miranti E; Ho DY; Enriquez K; Subramanian AK; Medeiros BC; Epstein DJ
    Leuk Lymphoma; 2022 Sep; 63(9):2206-2212. PubMed ID: 35410569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
    Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
    PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year review.
    Yeoh DK; Moore AS; Kotecha RS; Bartlett AW; Ryan AL; Cann MP; McMullan BJ; Thursky K; Slavin M; Blyth CC; Haeusler GM; Clark JE
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29275. PubMed ID: 34357688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?
    Guarana M; Nucci M
    Leuk Res; 2023 Aug; 131():107341. PubMed ID: 37327641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
    Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
    Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections.
    Hsu A; Matera R; Vieira K; Reagan JL; Farmakiotis D
    Support Care Cancer; 2021 Feb; 29(2):707-712. PubMed ID: 32435969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
    Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
    Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
    Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
    Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia.
    Fischer M; Spies-Weisshart B; Schrenk K; Gruhn B; Wittig S; Glaser A; Hochhaus A; Scholl S; Schnetzke U
    PLoS One; 2016; 11(3):e0150632. PubMed ID: 26963509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.